Edwards Lifesciences vs Moderna (EW vs MRNA)
Edwards Lifesciences (EW) vs Moderna (MRNA) in plain English: P/E, growth, margins, debt and dividend side by side, key differences and which fits each investor profile.
Edwards Lifesciences (EW) and Moderna (MRNA) compete in healthcare and pharma. Here are Edwards Lifesciences and Moderna side by side with their real figures as of November 4, 2026: what sets them apart, which fits each kind of investor and the most common questions, without telling you whether to buy Edwards Lifesciences or Moderna.
Edwards Lifesciences vs Moderna: the figures
| Figure | Edwards Lifesciences | Moderna |
|---|---|---|
| Share price | $99.37 (November 4, 2026) | $258.38 (November 4, 2026) |
| Market cap | $57.3 billion | $103.2 billion |
| P/E (TTM) | 59.1x | N/A |
| Forward P/E | 29.4x | N/A |
| Revenue growth (quarter) | +13.6% | +2.1% |
| Net margin (TTM) | 15.4% | -141.4% |
| Net debt / EBITDA | Net cash | N/A |
| Dividend yield | 0.00% | 0.00% |
| Beta | 0.83 | 1.17 |
Edwards Lifesciences and Moderna figures from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 4, 2026; N/A means that Edwards Lifesciences or Moderna figure is not available, and we never estimate it.
3 key differences between Edwards Lifesciences and Moderna
- Profitability: for every 100 of sales, Edwards Lifesciences keeps 15.4 as net profit and Moderna keeps -141.4.
- Growth: Edwards Lifesciences grew sales +13.6% year on year in its latest quarter, against +2.1% for Moderna.
- Volatility: Moderna stock moves more (beta 1.17) than Edwards Lifesciences (beta 0.83); the higher the beta, the more it amplifies market swings.
Edwards Lifesciences or Moderna: which fits your profile
- If you want growth: Edwards Lifesciences is growing faster today, so it fits better with investors who put business growth first, usually accepting a higher P/E and a bumpier ride.
- If you prefer caution: Edwards Lifesciences has a less volatile share price, which usually gives more room in a bad year.
Neither Edwards Lifesciences nor Moderna wins on everything, and owning both is also an option: spreading money across several companies or an index fund reduces what rides on each one.
How Edwards Lifesciences and Moderna make money
Edwards Lifesciences (EW)
Edwards Lifesciences makes artificial heart valves. Its biggest business is transcatheter aortic valve replacement, or TAVR, with the Sapien family, and it also sells mitral and tricuspid repair and replacement devices such as Pascal and Evoque, plus surgical valves. Hospitals in the United States, Europe and Japan are its main customers. Full Edwards Lifesciences analysis.
Moderna (MRNA)
Moderna develops messenger RNA vaccines and medicines. Nearly all of its sales come from respiratory vaccines: Spikevax and mNEXSPIKE for covid and mRESVIA for RSV. It sells to governments, health systems and pharmacies, mainly in the United States and Europe, and funds clinical trials in cancer and rare diseases. Full Moderna analysis.
Frequently asked questions: Edwards Lifesciences vs Moderna
Is Edwards Lifesciences or Moderna the better stock?
Choosing between Edwards Lifesciences and Moderna depends on what you are looking for. Edwards Lifesciences is growing faster right now. Fintols does not tell you whether to buy Edwards Lifesciences or Moderna: it shows you the differences so you can decide.
Which pays a higher dividend, Edwards Lifesciences or Moderna?
Neither pays a dividend as of November 4, 2026: Edwards Lifesciences and Moderna put what they earn into growth or other forms of shareholder return.
Can I own both Edwards Lifesciences and Moderna?
Yes. Many people spread their money across several companies, such as Edwards Lifesciences and Moderna, or use index funds so they do not depend on just one. If you are starting out, decide how much you want to invest and for how long before buying Edwards Lifesciences or Moderna.
More comparisons with Edwards Lifesciences or Moderna
More companies like Edwards Lifesciences and Moderna: healthcare and pharma stocks. Educational content about Edwards Lifesciences and Moderna, not investment advice.